- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Aquestive Therapeutics Inc (AQST)Aquestive Therapeutics Inc stock price live, this page displays NASDAQ AQST stock exchange data. View the AQST premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Aquestive Therapeutics Inc real time stock price chart below.
What Is the Aquestive Therapeutics Inc Stock Price Today?
The Aquestive Therapeutics Inc stock price today is 4.310.
What Is the Stock Symbol for Aquestive Therapeutics Inc?
The stock ticker symbol for Aquestive Therapeutics Inc is AQST.
Is AQST the Same as $AQST?
$AQST is a common way to refer to the Aquestive Therapeutics Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Aquestive Therapeutics Inc Trade On?
Aquestive Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Aquestive Therapeutics Inc a Good Stock to Buy?
Determining whether Aquestive Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Aquestive Therapeutics Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AQST quote. (ISIN: US03843E1047)
What Is the Aquestive Therapeutics Inc Stock Price Today?
The Aquestive Therapeutics Inc stock price today is 4.310.
What Is the Stock Symbol for Aquestive Therapeutics Inc?
The stock ticker symbol for Aquestive Therapeutics Inc is AQST.
Is AQST the Same as $AQST?
$AQST is a common way to refer to the Aquestive Therapeutics Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Aquestive Therapeutics Inc Trade On?
Aquestive Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Aquestive Therapeutics Inc a Good Stock to Buy?
Determining whether Aquestive Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Aquestive Therapeutics Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AQST quote. (ISIN: US03843E1047)
4.310
-0.080(-1.82%)
Closed
After Hours
4.291-0.019(-0.441%)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.270
4.450
52 wk Range
1.840
6.230
AQST Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.2704.450
52 wk Range
1.8406.230
Key Statistics
Edit
Book Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
UnlockN/A
(N/A)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockBook Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
UnlockN/A
(N/A)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockAQST Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Sell
Price Target
10.062
Upside
+133.457%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
2 analysts have revised their earnings downwards for the upcoming period
Aquestive Therapeutics Inc Company Profile
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson’s disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company’s proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
Aquestive Therapeutics Inc SWOT Analysis
Financial Outlook | Analysts maintain optimistic price targets around $9.00, reflecting confidence in Aquestive's progress and Anaphylm's market potential |
Market Dynamics | Delve into Anaphylm's potential market impact as a unique oral option, amidst evolving competition in non-injectable epinephrine treatments |
Regulatory Roadmap | Explore Aquestive's strategic timeline towards Anaphylm's NDA submission, with key milestones set for Q3 2024 through Q1 2025 |
Anaphylm's Promise | Aquestive Therapeutics nears FDA submission for Anaphylm, a groundbreaking oral epinephrine film for severe allergic reactions, challenging traditional injectors |
AQST Full Pro Research
Institutional-Grade Stock Analysis
Understand how AQST earns money
Financial health at a glance
Bearish and bullish outlooks
Latest expert insights
Actionable Pro Tips, and many more...
Gain access to 1400+ in-depth research reports on the most popular US stocks
Aquestive Therapeutics Inc Earnings Call Summary for Q3/2024
- Q2 2024 total revenues up 52% to $20.1M, driven by license and royalty revenue; revised 2024 outlook to $57-60M
- FDA approved Libervant for pediatric use; Anaphylm NDA filing expected December 2024; minimal cash burn projected
- R&D costs increased to $4.2M; manufacture and supply revenue decreased due to order timing
- Non-GAAP adjusted EBITDA loss of $20-23M expected for 2024; $5M revenue from Libervant projected for 2025
- Exploring partnerships for Anaphylm distribution; inbound interest received for commercial partnering or acquisition
Last Updated: 08/08/2024, 06:22 AM
Read Full TranscriptCompare AQST to Peers and Sector
Metrics to compare | AQST | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAQSTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −11.2x | −4.4x | −0.7x | |
PEG Ratio | 0.10 | −0.07 | 0.00 | |
Price / Book | −8.7x | 0.4x | 2.6x | |
Price / LTM Sales | 6.7x | 1.0x | 3.2x | |
Upside (Analyst Target) | 127.8% | 92.5% | 45.9% | |
Fair Value Upside | Unlock | 17.5% | 7.6% | Unlock |
Analysts' Recommendations
8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 10.063
(+133.47% Upside)
People Also Watch
FAQ
What Is the Aquestive Therapeutics (AQST) Stock Price Today?
The Aquestive Therapeutics stock price today is 4.31
What Stock Exchange Does Aquestive Therapeutics Trade On?
Aquestive Therapeutics is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for Aquestive Therapeutics?
The stock symbol for Aquestive Therapeutics is "AQST."
What Is the Aquestive Therapeutics Market Cap?
As of today, Aquestive Therapeutics market cap is 392.98M.
What is Aquestive Therapeutics Earnings Per Share?
The Aquestive Therapeutics EPS is -0.436.
What Is the Next Aquestive Therapeutics Earnings Date?
Aquestive Therapeutics will release its next earnings report on Mar 11, 2025.
From a Technical Analysis Perspective, Is AQST a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.